These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 9811714)

  • 1. Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells.
    Frankel SS; Steinman RM; Michael NL; Kim SR; Bhardwaj N; Pope M; Louder MK; Ehrenberg PK; Parren PW; Burton DR; Katinger H; VanCott TC; Robb ML; Birx DL; Mascola JR
    J Virol; 1998 Dec; 72(12):9788-94. PubMed ID: 9811714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
    Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells.
    Chomont N; Hocini H; Gody JC; Bouhlal H; Becquart P; Krief-Bouillet C; Kazatchkine M; Bélec L
    Virology; 2008 Jan; 370(2):246-54. PubMed ID: 17920650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies.
    Monini P; Cafaro A; Srivastava IK; Moretti S; Sharma VA; Andreini C; Chiozzini C; Ferrantelli F; Cossut MR; Tripiciano A; Nappi F; Longo O; Bellino S; Picconi O; Fanales-Belasio E; Borsetti A; Toschi E; Schiavoni I; Bacigalupo I; Kan E; Sernicola L; Maggiorella MT; Montin K; Porcu M; Leone P; Leone P; Collacchi B; Palladino C; Ridolfi B; Falchi M; Macchia I; Ulmer JB; Buttò S; Sgadari C; Magnani M; Federico MP; Titti F; Banci L; Dallocchio F; Rappuoli R; Ensoli F; Barnett SW; Garaci E; Ensoli B
    PLoS One; 2012; 7(11):e48781. PubMed ID: 23152803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient capture of antibody neutralized HIV-1 by cells expressing DC-SIGN and transfer to CD4+ T lymphocytes.
    van Montfort T; Nabatov AA; Geijtenbeek TB; Pollakis G; Paxton WA
    J Immunol; 2007 Mar; 178(5):3177-85. PubMed ID: 17312166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection.
    Sagar M; Akiyama H; Etemad B; Ramirez N; Freitas I; Gummuluru S
    J Infect Dis; 2012 Apr; 205(8):1248-57. PubMed ID: 22396600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.
    Quakkelaar ED; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Pantophlet R; Schuitemaker H
    J Virol; 2007 Aug; 81(16):8533-42. PubMed ID: 17522228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional evaluation of DC-SIGN monoclonal antibodies reveals DC-SIGN interactions with ICAM-3 do not promote human immunodeficiency virus type 1 transmission.
    Wu L; Martin TD; Vazeux R; Unutmaz D; KewalRamani VN
    J Virol; 2002 Jun; 76(12):5905-14. PubMed ID: 12021323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.
    Wolbank S; Kunert R; Stiegler G; Katinger H
    J Virol; 2003 Apr; 77(7):4095-103. PubMed ID: 12634368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4 coexpression regulates DC-SIGN-mediated transmission of human immunodeficiency virus type 1.
    Wang JH; Janas AM; Olson WJ; KewalRamani VN; Wu L
    J Virol; 2007 Mar; 81(5):2497-507. PubMed ID: 17151103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.
    Verrier F; Nádas A; Gorny MK; Zolla-Pazner S
    J Virol; 2001 Oct; 75(19):9177-86. PubMed ID: 11533181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes.
    Su B; Lederle A; Laumond G; Ducloy C; Schmidt S; Decoville T; Moog C
    J Virol; 2014 Sep; 88(18):10975-81. PubMed ID: 24965460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human IgM monoclonal antibodies block HIV-transmission to immune cells in cervico-vaginal tissues and across polarized epithelial cells in vitro.
    Devito C; Ellegård R; Falkeborn T; Svensson L; Ohlin M; Larsson M; Broliden K; Hinkula J
    Sci Rep; 2018 Jul; 8(1):10180. PubMed ID: 29977063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capture and transfer of simian immunodeficiency virus by macaque dendritic cells is enhanced by DC-SIGN.
    Yu Kimata MT; Cella M; Biggins JE; Rorex C; White R; Hicks S; Wilson JM; Patel PG; Allan JS; Colonna M; Kimata JT
    J Virol; 2002 Dec; 76(23):11827-36. PubMed ID: 12414925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.
    Mascola JR; Lewis MG; VanCott TC; Stiegler G; Katinger H; Seaman M; Beaudry K; Barouch DH; Korioth-Schmitz B; Krivulka G; Sambor A; Welcher B; Douek DC; Montefiori DC; Shiver JW; Poignard P; Burton DR; Letvin NL
    J Virol; 2003 Oct; 77(19):10348-56. PubMed ID: 12970419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.
    Gombos RB; Kolodkin-Gal D; Eslamizar L; Owuor JO; Mazzola E; Gonzalez AM; Korioth-Schmitz B; Gelman RS; Montefiori DC; Haynes BF; Schmitz JE
    J Virol; 2015 Aug; 89(15):7813-28. PubMed ID: 25995259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins.
    Li A; Baba TW; Sodroski J; Zolla-Pazner S; Gorny MK; Robinson J; Posner MR; Katinger H; Barbas CF; Burton DR; Chou TC; Ruprecht RM
    AIDS Res Hum Retroviruses; 1997 May; 13(8):647-56. PubMed ID: 9168233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.
    Mehandru S; Wrin T; Galovich J; Stiegler G; Vcelar B; Hurley A; Hogan C; Vasan S; Katinger H; Petropoulos CJ; Markowitz M
    J Virol; 2004 Dec; 78(24):14039-42. PubMed ID: 15564511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.
    Mascola JR; Louder MK; VanCott TC; Sapan CV; Lambert JS; Muenz LR; Bunow B; Birx DL; Robb ML
    J Virol; 1997 Oct; 71(10):7198-206. PubMed ID: 9311792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.